Resources

First results from phase 3 CANVAS trial show canagliflozin as add-on therapy to insulin lowered blood sugar levels in patients with type 2 diabetes at an elevated risk for cardiovascular disease…. Canagliflozin was also shown to be effective and generally well-tolerated in patients with type 2 diabetes aged 55 to …

Researchers have identified a mitochondrial target through which insulin sensitizers achieve their anti-diabetic effects…. 

Eli Lilly and Boehringer Ingelheim announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes…. 

The use of an outpatient electronic health record (EHR) system, rolled out across 17 medical centers, was associated with improvements in clinical outcomes and health care utilization in a study population of nearly 170,000 people with diabetes…. 

Kidney disease is a significant predictor of all-cause mortality and end-stage renal disease (ESRD) in patients with and without hypertension or diabetes, according to two large meta-analyses…. 

Insulin degludec, an investigational insulin with a prolonged half-life and a reportedly flatter pharmacokinetic profile with fewer high and low levels, showed a modest hypoglycemic edge over insulin glargine in a 52-week head-to-head comparison in patients with type 2 diabetes….

Amy P. Campbell, MS, RD, CDE, and Richard S. Beaser, M.D. The weeks excerpt answers the following questions: When to take vitamins? Who should take vitamins? Can chromium really lower blood sugars? Is vitamin E recommended? Is too much vitamin E harmful? Does cinnamon really work? What dose of cinnamon …

  In this week’s Homerun Slides, we begin a new series on Infections in Patients with Diabetes. In this first set, topics covered include the reasons for these increased infections as well as examples of some of the types of infections which diabetes patients are particularly vulnerable to….

  By Sheri Colberg, PhD    Any type of exercise training can make your insulin work better, regardless of what type of diabetes you have and whether you have to take insulin.

  PaQ Insulin Delivery Device   The CeQur device (PaQ), a small discreet, wearable insulin patch infuser, is for continuous subcutaneous delivery. The CeQur insulin infuser includes a disposable insulin reservoir that attaches to a reusable electronic messenger. The device easily attaches to the patient’s abdominal area with a secure adhesive …